Novartis AG (NVS)
| Market Cap | 249.49B |
| Revenue (ttm) | 56.37B |
| Net Income (ttm) | 14.39B |
| Shares Out | 1.92B |
| EPS (ttm) | 7.30 |
| PE Ratio | 17.33 |
| Forward PE | 15.01 |
| Dividend | $2.60 (1.99%) |
| Ex-Dividend Date | Mar 12, 2025 |
| Volume | 1,312,012 |
| Open | 130.16 |
| Previous Close | 130.26 |
| Day's Range | 129.85 - 131.19 |
| 52-Week Range | 96.06 - 134.00 |
| Beta | 0.44 |
| Analysts | Sell |
| Price Target | 118.00 (-9.54%) |
| Earnings Date | Oct 28, 2025 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NVS stock is "Sell." The 12-month stock price target is $118.0, which is a decrease of -9.54% from the latest price.
News
Why Novartis Stock Topped the Market Today
It earned FDA approval for a spinal muscular atrophy drug. This is a version of its existing commercialized SMA treatment, Zolgensma.
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
On Monday, the U.S. Food and Drug Administration (FDA) approved Novartis AG's (NYSE: NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and older, teens, and adults with spinal muscul...
Novartis plans to cut up to 550 jobs at Swiss facility
Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2...
Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community
The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The only gene replacement therapy for children two years and older, teens, and...
FDA approves Novartis' gene therapy for rare muscle disorder
U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said on Monday.
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III s...
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology...
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into...
Novartis Expects Steady Sales Growth Through 2030
The pharma giant said it is well positioned beyond the decade, citing higher expectations for key drugs.
Novartis targets 5%-6% annual sales growth until 2030 on key drugs
Switzerland's Novartis on Thursday projected currency-adjusted sales growth of 5% to 6% until 2030 for the group, underpinned by higher peak revenue expectations for its drugs Kisqali and Scemblix.
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc 1 Peak sales guidance upgraded for K...
Novartis to build manufacturing hub in North Carolina, creating 700 jobs
Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U.S. infrastructure investment over the next five years, the Swiss pharmac...
Novartis announces plans to build flagship manufacturing hub in North Carolina
Basel, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end...
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at th...
New, effective anti-malaria drug could help fight rising resistance, says Novartis
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final-stage trial resul...
Novartis opens new plant in California to make cancer drugs
Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. s...
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Basel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) ...
Meharry and Novartis Partner on HEART Initiative for Healthier Communities
NASHVILLE, Tenn.--(BUSINESS WIRE)--The School of Global Health at Meharry Medical College, in partnership with Novartis, today announced the launch of Health Assessments and Rapid Transformation (HEAR...
Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
Novartis AG ( NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDT Company Participants Isabella Zinck Shreeram Aradhye - President of Develop...
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the American ...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirs...
Novartis completes acquisition of Tourmaline Bio
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common s...